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Abstract
Respiratory syncytial virus (RSV) is an important cause of severe upper and lower respiratory disease in infants and in the
elderly. There are 2 main RSV subtypes A and B. A recombinant vaccine was designed based on the central domain of the
RSV-A attachment G protein which we had previously named G2Na (aa130–230). Here we evaluated immunogenicity,
persistence of antibody (Ab) response and protective efficacy induced in rodents by: (i) G2Na fused to DT (Diphtheria toxin)
fragments in cotton rats. DT fusion did not potentiate neutralizing Ab responses against RSV-A or cross-reactivity to RSV-B.
(ii) G2Nb (aa130–230 of the RSV-B G protein) either fused to, or admixed with G2Na. G2Nb did not induce RSV-B-reactive Ab
responses. (iii) G2Na at low doses. Two injections of 3 mg G2Na in Alum were sufficient to induce protective immune
responses in mouse lungs, preventing RSV-A and greatly reducing RSV-B infections. In cotton rats, G2Na-induced RSV-
reactive Ab and protective immunity against RSV-A challenge that persisted for at least 24 weeks. (iv) injecting RSV primed
mice with a single dose of G2Na/Alum or G2Na/PLGA [poly(D,L-lactide-co-glycolide]. Despite the presence of pre-existing
RSV-specific Abs, these formulations effectively boosted anti-RSV Ab titres and increased Ab titres persisted for at least 21
weeks. Affinity maturation of these Abs increased from day 28 to day 148. These data indicate that G2Na has potential as a
component of an RSV vaccine formulation.
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Introduction
RSV is a viral pathogen causing a range of symptoms from mild
upper to severe lower respiratory tract infection in infants, in
immunocompromised individuals and in the elderly [1,2]. Every
year in the US, 75,000–125,000 children ,1 year old are
hospitalised and an estimated 250 deaths occur, due to RSV
infection. It is responsible for 1.5 million outpatient visits among
children aged ,5 years annually in the US [3]. Natural RSV
primary infections do not confer complete protection. Despite
many decades of research and development, an RSV vaccine is
still not available.
The formalin-inactivated RSV vaccine tested in field trials in
the 1960s caused enhanced disease in vaccinated infants. These
factors have greatly complicated the development of a safe and
efficacious RSV vaccine [4]. Research and development of
immunoprophylaxis (vaccines and humanised monoclonal Ab)
against RSV were recently reviewed by Power [5], Graham [6],
van Bleek [7] Chang [8] and Collins [9]. RSV F and G
glycoproteins are the protective antigens inducing neutralizing Ab
against RSV infection. Both F and G proteins and peptides have
been subjected to numerous clinical trials. Among them, G2Na,
the central conserved region of RSV-A attachment glycoprotein G
(aa130–230) (Fig. 1A & 1B) has been tested in the subunit vaccine
candidate BBG2Na [10,11,12]. G2Na was C-terminally fused to
BB, the albumin binding domain of Streptococcal protein G.
BBG2Na reached clinical phase III but was halted due to rare
adverse events in a very small number of vaccinees. The
chronology of the events, the delay to onset and the symptoms
were suggestive of a vaccine-related type III hypersensitivity-like
reaction. When tested in a rabbit model of type III hypersensi-
tivity, we found that BBG2Na induced an Arthus reaction and that
the BB component, rather than G2Na, was responsible [13]. This
provided the impetus for further studies on the immunogenicity
and protective efficacy of G2Na as an RSV vaccine component.
This non-glycosylated fragment includes a 13 aa peptide that is
completely conserved between all known A and B strains, a
correctly linked cysteine noose formed by 4 conserved Cys residue
(res.) [14], a heparin binding domain [15] and a CX3C chemokine
motif [16]. G2Na contains 5 human B cell epitopes (2 of which
overlap) called protectopes [17,18], including a highly immuno-
genic peptide (G174–187) [19], and a Th epitope (G184–198)
[20]. The conserved Cys res. play an important role in the
enhancement of CTL responses towards other RSV antigens (Ag)
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protein P40, the outer membrane protein A from Klebsiella
pneumoniae) induced protective immune responses against RSV-A
challenge [17]. Passive-transfer of Mabs (generated against the
central domain G peptides) protect animal lungs from RSV
challenge without enhanced immunopathology [22,23,24]. Fur-
thermore, immunization with G peptides or protein spanning the
central conserved region induced Abs that block the CX3C-
CX3CR1 interaction of RSV G protein and reduced pulmonary
inflammation and virus replication in mice [25].
In this study, we documented in rodents the immunogenicity
and protective efficacy of the 11.8 KDa G2Na or G2Nb (the RSV
B-derived equivalent of G2Na), genetically fused or not with
carrier proteins. The vaccine candidates were variously formulated
in Alum or PLGA and compared. In particular, we report the
induction and duration of protective immunity following vaccina-
tion and heterologous protective immunity against RSV B.
Furthermore, in a mouse model mimicking pre-existing RSV
immunity, we determined the capacity of G2Na vaccine
formulations to boost and cause affinity maturation of the Ab
response following live RSV priming. Our data provide the
rationale for further studies of G2Na as an RSV vaccine
component.
Materials and Methods
Viruses, cells, viral ELISA antigens
RSV-A Long strain (ATCC VR-26, American Type Culture
Collection, Rockville, MD), and strain BT2a, (derived from an
infant hospitalised with bronchiolitis and isolated in Dr. Power’s
laboratory) as well as RSV-B strain 8/60 (kindly provided by Dr.
G. Taylor, Institute of Animal Health, Compton, UK) and strain
CH18537 (kindly provided by Prof. Geoff Toms, University of
Newcastle-upon-Tyne, UK) were propagated in HEp-2 cells
(ECACC 86030501, European Collection of Animal Cell
Cultures, Porton Down, Salisbury, UK) as previously described
[19], except that DMEM was supplemented with 1% fetal calf
serum. Viruses were harvested when extensive cytopathic effect
was evident, by scraping attached cells into the medium. Purified
viral antigens were generated by ultra-centrifugation of stocks of
each virus on a discontinuous sucrose gradient, pelleting purified
virions and resuspending the pellets in 0.5% (v/v) IGPAL (Sigma
Aldrich, UK) in H2O. The protein content of the virus ELISA
antigen stock was measured using the NanoOrange Protein
Quantification kit (Molecular Probes, Invitrogen) and an appro-
priate protein dilution to be used in the ELISA assays were
determined in a checker board assay.
Gene constructs, production and purification of
recombinant proteins
For the first experiment, we designed 3 fusion molecules
G2NaDTa, G2NaDTb, G2NaDTaDTb where: DTa (aa1–185)
the A subunit of DT where res. Gly 52 was substituted by Glu, this
single change was shown to deactivate the toxicity of DT namely
CRM 197 [26]; DTb (aa 202–456) is the transmembrane domain
B subunit of DT and DTaDTb is the fusion molecule of both
(Fig. 2A). DT, in particular CRM 197, is commonly used as carrier
protein for non immunogenic Ag like polysaccharides (conjugate
vaccine) in licensed human vaccines. For comparison, we also
included in this experiment BBG2Na, where BB (albumin binding
domain of Streptococcal protein G) was characterised as a carrier
protein [27]. For the 2
nd experiment, G2Nb was designed similarly
to G2Na (Fig. 2B) from aa 130 to 230 of RSV-B (8/60 strain) G
protein comprising the 13 aa conserved peptides and the 4 Cys
conserved res.. In the fusion protein G2ab, G2Na cysteine noose
was kept intact (Fig. 1A) but in the G2b cysteine loop region, the 2
outer Cys (C173 and C186) were substituted by Ser res. (Fig. 2B).
This was designed to minimise non-desired inter or intra disulfide
bridges which could alter the conformational structure of the
cysteine noose. Recombinant Ags were expressed in E. coli: G2Na,
G2NaDTa, G2NaDTb, G2NaDTaDTb, G2Nb, G2ab and
BBG2Na. Genes encoding G2Na and G2Nb were assembled
using synthetic oligonucleotides designed with optimised usage
codon for E. coli, according to Nguyen [28]. In G2ab where the
2 Cys (C173 and C186) res. of the G2Nb were substituted by Ser
res., we used PCR-mutagenesis to change Cys res. into Ser res.
The 2
nd step was gene fusion to G2Na to generate a gene encoding
G2ab. Genes encoding DTa and DTb were obtained by PCR
directly on Corynebacterium diphtheriae genomic DNA (ATCC,
Rockville, MD). Site directed PCR-mutagenesis was performed
to change Gly (aa52) into Glu in the DTa. Gene constructs
encoding G2NaDTa, G2NaDTb, G2NaDTaDTb were subcloned
Figure 1. Central conserved domain of RSV G attachment protein (aa130–230). We present here the aa sequence of the conserved domain
of (A) G2Na in a hypothetical schematic 2D structure with the highly conserved 13 aa domain followed by the Cysteine noose (dotted circle)
[sequence in brackets with Cys res. in bold]. Note the disulphide bridge between the Cys res. and the Lys rich heparin binding domain. (B) G2Na
derived from RSV-A (Long) G protein compared to G2Nb derived from RSV-B (8/60) G protein from aa121–240. Conserved domains are underlined.
Cys res. positions in bold letters are respectively 173, 176, 182 and 186. (* divergent).
doi:10.1371/journal.pone.0034331.g001
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antigens were produced in E.coli ICONE cells and recovered as
inclusion bodies, before extraction, refolding and purification [29].
These proteins were purified via the His Tag on an IMAC column
with high yield and high purity. Clinical grade G2Na and
BBG2Na were obtained after purification to homogeneity by a five
chromatography step procedure including anion exchange, size
exclusion chromatography and hydrophobic interaction chroma-
tography. BBG2Na and G2Na primary structures were confirmed
by ES-MS (Electrospray Mass spectrometry) [14].
Antigens formulations in Alum or in PLGA
Antigens were adsorbed to Alum (Alhydrogel or Adju-Phos,
Superfos BioSector, Danmark) in PBS before injections. In each
experiment the quantity of each fusion protein was calculated as
equivalents in molarity amounts to G2Na.
For the last experiment, biodegradable polymeric particles were
used to encapsulate G2Na antigen. They represent an exciting
approach to control the release of vaccine antigens to reduce the
number of injections in the immunization schedule and optimise
the desired immune response via selective targeting of antigen to
antigen presenting cells [30,31]. The hypothesis was based on the
idea that intermittent intra-corporal release of antigen over a
period of months might periodically boost the RSV-specific
immune responses and thereby maintain elevated antibody titres
over a longer period. G2Na-loaded PLGA microspheres were
prepared by water/oil/water emulsion/solvent evaporation meth-
od using a 75:25 PLGA copolymer (Boehringer Ingelheim),
intrinsic viscosity of about 0.6 dL/g, which contains alkyl ester
end groups. 173.3 ml of methylene chloride were added to 25.5 g
of PLGA. 23 ml of a concentrated solution of G2Na (18 mg/ml) in
a phosphate buffer solution (pH 7.5) were added to the PLGA
organic solution and emulsified by sonication. This primary
emulsion was added using a pump to an external phase consisting
of an aqueous solution of 8% (w/v) polyvinyl pyrrolidone K90,
0.37 (v/v) polysorbate 80 and 1% (w/v) sodium chloride and
mixed in order to emulsify. A volume of purified water was added
and the methylene chloride was allowed to evaporate by bubbling.
The resultant microspheres were sieved through a 90 mm mesh,
collected by filtration, washed 3 times, and then freeze dried (Fig.
S1). The average diameter of the microspheres was 14.8 mm, while
microencapsulation efficiency was 68%. Blank microspheres were
prepared by o/w emulsion/solvent evaporation method using a
75:25 PLGA copolymer, intrinsic viscosity of about 0.6 dL/g,
which contains alkyl ester end groups. Controls: after mild
dissolution of G2Na-loaded PLGA microspheres with acetone
followed by precipitation of the proteins, it was found that the
majority of microencapsulated G2Na was recovered (.85%). By
ELISA assays using the G2Na-specific Mab 18D1, which
recognises the cysteine noose protectope [17], it was found that
about 90% of the incorporated protein were structurally well-
conserved.
Animals and Immunisations
Female BALB/c mice, aged 6–9 weeks, were purchased from
IFFA CREDO (L’Arbresle, France) and kept under specific
pathogen-free conditions. They were fed with mouse maintenance
diet A04 (UAR, Villemoissin-sur-Orge, France) and water ad
libitum, and were housed and manipulated according to French
and European guidelines. Five to eight week old male cotton rats
(Sigmodon hispidus) were purchased from Virion Systems Inc.
(Rockville, MD, USA), housed individually and kept under specific
pathogen-free conditions. The cotton rats received sterile food and
water ad libitum and were housed and manipulated according to
French, UK and European guidelines. Mice and cotton rats were
confirmed seronegative vis-a `-vis RSV before inclusion in the
studies.
Animals were immunised intraperitoneally (ip) with a 200 ml
volume, or intramuscularly (im) with a 100 ml volume, in PBS
containing 20% Alhydrogel or Adju-Phos. Palivizumab (SynagisH,
Abbott Lab.), a humanised monoclonal antibody specific for the
RSV F protein, is the only RSV-specific product on the market
and is used prophylactically [32]. Palivizumab was used at 2 doses:
1.25 mg/Kg and 5 mg/Kg in PBS. Cotton rats were injected im
with palivizumab one day before RSV challenge.
Figure 2. Schematic presentation of recombinant G protein derivatives. The gene encoding G2Na was fused to (A) DT derivatives resulting
in G2NaDTa, G2NaDTb and G2NaDTaDTb. DTa was subcloned the nucleotide sequence encoding (aa1–185) of the catalytic domain of DT as
described in Materials and Methods. Note that Gly res. at aa52 was substituted by Glu in order to inactivate DT toxicity. DTb was subcloned from the
nucleotide sequence encoding (aa202–456) of the transmembrane domain of DT. DTaDTb is a fusion product of DTa to DTb. (B) G2b (aa130–230) of
RSV-B G protein (8/60 strain) resulting in G2ab: in this fusion form, G2Na has 4 conserved Cys but G2b has only 2 conserved Cys176 and 182, the 2
outer Cys173 and Cys186 were substituted by Ser res. in order to avoid spurious disulphide bridges. G2Nb used for admixing with G2Na has all four
Cys res.
doi:10.1371/journal.pone.0034331.g002
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RSV-A strains included Long (ATCC VR-26) and BT2a
(clinical isolate). The RSV-B strains included CH18537 and 8/
60. As indicated in each experiment, animals were bled according
to the experimental schedule. G2Na-, G2Nb-, RSV-A- and RSV-
B-specific IgG titres were determined by ELISA as previously
described [10] using goat anti-mouse IgG-HRP conjugate (Jackson
Immuno Research Laboratories, Baltimore, MD) or rabbit anti-
cotton rat IgG (Virion Systems Inc., USA) followed by HRP-
conjugated affinity purified goat anti-rabbit IgG (ICN). Mouse
ELISA titres were expressed as the reciprocal of the last dilution
with an OD (450 nm) at least twofold that of the negative control.
A positive control serum (heat-inactivated at 56uC for 30 min)
from cotton rats immunised with G2Na formulated in TiterMax
Gold were included in all ELISA plates. Rat ELISA titres are
referred to as arbitrary units and are calculated on the basis of
regression analysis in relation to the positive control serum serial
dilution curve, in which the first dilution is arbitrarily assigned a
value of 10,000. Immunised animals were challenged with 10
5
tissue culture infectious doses50 (TCID50) RSV-A or 10
6 (TCID50)
RSV-B by intranasal (in) installation and sacrificed 5 days post-
challenge. To determine protective efficacy, animals were
anesthetised and exsanguinated by cardiac puncture. Lung
removal, lung homogenate preparation and virus titrations were
undertaken as previously described [10]. The limit of detection for
lung tissues was #1.45 log10 TCID50/g of lung, except when
insufficient lung homogenate was available to inoculate 4 wells
with undiluted homogenate, in which case the detection limit was
determined as a function of the number of wells (1–3) inoculated
with undiluted homogenates. Animal lungs were considered
protected when mean virus titres were reduced by at least 2
log10 relative to PBS-immunised control animals.
Avidity determination
Avidity of anti-RSV-A IgG Ab was determined by an ELISA
elution assay using thiocyanate (NH4SCN) as a chaotropic agent
(Sigma, St Louis, MO)[33]. Sera were pre-titrated and adjusted by
dilution to a concentration giving ELISA results in the upper
portion of the linear part of the standard curve (OD (450 nm)
approx. 1.5). Following incubation of serum dilutions, NH4SCN
was added at a final concentration ranging from 0 to 6 M (mole/
L). Plates were then incubated for 15 min at room temperature,
prior to the addition of the goat anti-mouse IgG-HRP conjugate
and finally HRP substrate. The amount of Ab remaining bound to
the plate, at each NH4SCN concentration, was calculated in units
by reference to the ELISA standard curve. The avidity index (AI),
corresponding to the concentration of thiocyanate required to
elute 50% of the Ab units, was calculated. Low avidity Ab were
defined by the fraction eluted at ,3MN H 4SCN concentrations,
whereas high-avidity IgG Ab were defined as those only eluted at
$3MN H 4SCN concentrations according to [49].
Statistical analyses
Antibody titres were analysed using SigmaStatH 3.5 statistical
software using ANOVA followed by Holm-Sidak test on log10
values. Results were considered statistically significant if p,0.05.
Ethics statement
Procedures and experiments involving mice and cotton rats
were performed in accordance with French legislation under
personal licence number 74-16 and this work was performed
under the agreement C 74-243-8 obtained from the ‘‘Direction
De ´partementale des services ve ´te ´rinaires de Haute-Savoie’’. The
experiments on cotton rats (chapter duration of protective
immunidy induced by G2Na in cotton rats) were performed
under personal licence number PIL982b and project licence
PPL2595b, both issued by the Northern Ireland Department of
Health, Social Services and Public Safety, pursuant to the Animals
(Scientific Procedures) Act 1986.
Results
Immunogenicity and protective efficacy conferred by G
fragment constructs in cotton rats
G2Na is the RSV G protein component of the well
characterised RSV vaccine candidate BBG2Na [10,11]. However,
there is limited information concerning the vaccine potential of
G2Na without BB. In view of the adverse events encounter with
BBG2Na in Phase III clinical trials, and the demonstration that
the BB component was likely responsible for them, we generated a
series of constructs incorporating G2Na and diphtheria toxin
derivates as fusion carrier protein partners with a view to
producing a novel RSV vaccine candidate. The constructs
included G2NaDTa (G2Na N-terminal fused to Diphtheria
subunit A, DTa), G2NaDTb (G2Na N-terminal fused to
Diphtheria subunit B, DTb) and G2NaDTaDTb (Fig. 2A). The
immunogenicity and protective efficacy of these constructs in
cotton rats were compared with BBG2Na and G2Na alone.
Cotton rats received im 3 doses of 6 mg equivalent of G2Na in
Alum: G2Na, BBG2Na, G2NaDTa, G2NaDTb, G2NaDTaDTb
(Fig. 3A protocol). For simplicity, only ELISA IgG titres at day 60
(1 month after the 3
rd injection) are shown (Fig. 3B & 3C). Ab
responses induced against G2Na or RSV-A were similar between
the 5 groups after the 3
rd dose. The 2
nd dose induced similar anti-
RSV-A Ab titres to the 3
rd dose (not shown). Importantly, lungs
from cotton rats immunised with G2Na, BBG2Na or G2NaDTb
were fully protected (virus at or below the limit of detection)
against RSV-A challenge (Fig. 3D). Furthermore, mean lung virus
titres in groups immunised with G2NaDTa or G2NaDTaDTb
were also consistent with protection, while 3/6 cotton rats in both
groups had no detectable virus. These data indicate that G2Na
alone is highly immunogenic and protective against RSV-A
challenge in cotton rats. Surprisingly, they also suggest that the BB
or DT-derived carrier proteins do not enhance the immunoge-
nicity or protective efficacy of G2Na in this model.
Heterologous anti-RSV-A and RSV-B Ab responses
induced by G fragment constructs in mice
RSV strains are separated into the A and B subgroups based
primarily on the G protein sequence. Indeed, there is limited
antibody cross-reactivity between native G proteins from each
subgroup. We previously demonstrated that BBG2Na induced
efficient but short term protective immunity against RSV B
challenge in mice [34]. In an attempt to improve heterologous
protective immunity, we constructed and expressed G2Nb, the
RSV B (strain 8/60) G protein equivalent of G2Na, separately or
fused to G2Na (G2ab) (Fig. 2B). G2Nb incorporates the 4
conserved Cys res. (see alignment Fig. 1B). The G2ab fusion
protein contains G2Na (4 Cys) and the B component of G2
modified to contain only 2 Cys (Fig. 2B). Cys173 and Cys186 were
substituted by Ser res. in the B component G fragment in order to
limit the number of Cys res. in the fusion protein G2ab and to
minimise spurious disulfide bonds between Cys res.. The rationale
for this approach was provided by Simard et al. [34], who reported
that a subgroup B G peptide with only 2 conserved Cys176 and
Cys182 (peptide B174187.S186) induced protective immune
responses against RSV-B.
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addition, we determined whether G2Na admixed with G2Nb or
G2ab improved the Ab reactivity with RSV-B. (Fig. 2B). Groups
of naı ¨ve mice were immunised im twice with 6 mg of each of the
following antigens formulated in Alum: G2Na, G2Nb, G2ab,
G2Na admixed with G2Nb, according to the protocol in Fig. 4A.
Similar IgG antibody titres against G2Na were found in all groups,
except in the G2Nb-immunised mice (Fig. 4B). In the other
groups, high anti-G2Na Ab responses were evident after a single
immunisation. Furthermore, mean antibody titres were boosted
after the second dose. In contrast, the second injection of G2Nb
did not boost Ab reactivity with G2Na, which was rather weak
(#3log10) compared to the other groups (p#0.05). This might be
explained by the fact that G2Nb shares only 52.5% sequence
homology with G2Na (see alignment of Fig. 1B).
After the first injection, G2Na induced higher mean Ab
reactivity with G2Nb in mice than G2Nb (Fig. 4C). After the
second injection, on day 45, every immunised group had
equivalent Ab reactivity with G2Nb that remained stable until
day 60. Surprisingly, the presence of the subgroup B G fragment,
either in the genetic fusion form G2ab or admixed with G2Na, did
not boost the Ab reactivity with G2Nb.
On day 60, high levels of Ab reactivity with RSV A were
evident in all mice immunised with G2Na alone, admixed with
G2Nb or fused in G2ab (Fig. 4D). In contrast, G2Nb-immunised
mice developed significantly lower RSV-A Ab reactivity, consis-
tent with the poor G2Na Ab reactivity described above. Ab
reactivity with RSV-B was also evident in each of these groups in
similar relative amounts, although they were approximately 0.5
log10 lower than the anti-RSV-A Ab titres. Again, G2Nb was
poorly immunogenic and Abs did not react with RSV-B,
suggesting that the G2Nb fragment was misfolded. Collectively,
these data showed that its presence did not boost Ab reactivity
with RSV-B when associated with G2Na.
Immunogenicity and protective efficacy of G2Na against
both RSV-A and B strains
To determine the capacity of G2Na to induce protective
immunity against both RSV-A and B challenges in mice, naı ¨ve
BALB/c mice were immunised ip with 2 doses of either 0.5 mgo r
3 mg of G2Na with a 2 week interval (Fig. 5A). At day 34, half of
the group (5/10) was challenged with RSV-A, while the other half
was challenged with RSV-B. After the second injection, high Ab
titres were detected in both the G2Na and RSV-A ELISAs
(Fig. 5B). Importantly, these titres, particularly in the groups
immunised with 3 mg G2Na, were consistent with those reported
in Figs. 4B and 4D, respectively. Also consistent with Fig. 4D, Ab
titres against RSV-B were lower than titres against G2Na or RSV-
A. While mean Ab titres against G2Na and RSV-A suggest a slight
dose effect, the differences were not significant. After homologous
challenge with RSV-A, there was no detectable virus present in the
lungs of G2Na-immunised mice, irrespective of the dose (Fig. 5C).
After heterologous challenge of 3 mg G2Na-immunised mice with
RSV-B, there was also no virus detected in 4/5 mice. However,
virus was detected in the 5
th mouse. The mean titre of all 5 RSV-B
Figure 3. Immunogenicity and protective efficacy against RSV-
A conferred by G2Na, BBG2Na, G2NaDTa, G2NaDTb and
G2NaDTaDTb in cotton rats. Groups of animals were immunised
thrice im with G2Na derivatives according to the outlined experimental
protocol (A). After the 3
rd injection, on D60, we determined by ELISA
the (B) anti-G2Na IgG Ab titre, (C) anti-RSV-A (Long) IgG Ab titre. Five
days after challenge with RSV-A (10
5 TCID50) we evaluated protective
efficacy by determining the RSV-A titre in the lungs of immunised
animals. Data were expressed as Log10 TCID50/g lung tissue. The dotted
line represents the detection limit of RSV-A in the lungs.
doi:10.1371/journal.pone.0034331.g003
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in lung titres of RSV-B was evident in mice immunised with 0.5 mg
G2Na compared to controls, 3/5 mice had detectable virus in
their lungs and the mean titre was above the cut-off for protection
(.2log10 reduction). This is consistent with a study in which
animals immunised thrice ip with 0.2 or 20 mg of BBG2Na
demonstrated good protective immunity against RSV-B with the
higher dose but less so with the lower dose [35].
Duration of protective immunity induced by G2Na in
cotton rats
An important consideration for an RSV vaccine is that it is
capable of inducing protective immune responses that persist for
longer than the normal epidemic RSV season, i.e., ,5 months. To
address this, groups of cotton rats received 2 im injections of 6 mg
G2Na. The kinetics of IgG responses was measured by ELISA
against 3 RSV strains: Long (RSV A) from which G2Na peptide
sequence was derived, BT2a (RSV A) a recent clinical isolate and
CH18537 (RSV-B). As positive controls for Ab-mediated protec-
tion, 2 animal groups received im respectively 1.25 mg/Kg and
5 mg/Kg SynagisH one day before RSV A challenge (Fig. 6A
protocol). The second injection of G2Na resulted in a significant
boost in Abs reactive with anti-RSV-A Long (blue circle), which
peaked at day 49 and declined slowly until day 148. It is
noteworthy that the kinetics of RSV-A BT2a reactivity (red
square) paralleled those of RSV-A Long until day 105, albeit at
slightly lower titres, but appeared to decline more rapidly by the
last point, day 148. As expected, based on the data presented in
Figs. 4D and 5B, the kinetics of, and peak, Ab reactivity with
RSV-B CH18537 (green triangle) were lower than the reactivity
with RSV-A. Nonetheless, reactivities to RSV-B persisted for the
duration of the experiment. Challenge at day 142 with infectious
RSV-A (Long), produced no infectious virus in the lungs of G2Na-
immunised cotton rats when assessed 5 days later (Fig. 6C). This
protective efficacy compared favourably with positive control
naı ¨ve cotton rats that received SynagisH prophylaxis (5 mg/kg) 1
day before challenge. The animal group receiving a lower dose
(1.25 mg/Kg) was partially protected (RSV-A titre=1.5860.21
log10 TCID50. Virus was detected in 3/6 lung homogenates).
Therefore, two injections of G2Na/Alum in cotton rats were
sufficient to induce persistently elevated Ab responses capable of
recognizing both RSV-A and, to a lesser extent, RSV-B for at least
21 weeks. Importantly, G2Na also induced persistent protective
immunity against RSV-A in cotton rats.
Induction of Ab responses in RSV primed mice by G2Na/
Alum and G2Na/PLGA and Ab affinity maturation
In the context of the annual autumn Flu vaccine, it would be
ideal to administer an RSV vaccine to the elderly at the same time
as the influenza virus vaccine, as RSV and influenza virus are the
most important viral pathogens causing severe RTI in this
population and both circulate in the winter time [1,2,37]. In an
attempt to model vaccine responses in RSV seropositive elderly,
we addressed the immunogenicity of G2Na in RSV-A-primed
mice, in which G2Na adsorbed to Alum (G2Na/Al) was compared
to G2Na encapsulated in PLGA (Fig. S1). We also examined the
avidity of Ab induced against RSV-A over time. RSV-A-primed
mice were injected im with a single dose of G2Na encapsulated in
PLGA. The aim was to have intermittent intra-corporal release of
antigen over a period of months that might boost RSV-specific
immune responses and thereby maintain elevated antibody titres
over a longer period.
Mice were primed by in administration of 10
5 TCID50 RSV-A.
Three weeks later, sera were screened for presence of anti-RSV Ab
before im injection (Fig. 7A). RSV-A-primed mice were injected im
with G2Na/AL, G2Na/PLGA or control empty PLGA. In the
control empty PLGA group (no antigen added), RSV-A Ab levels
(white bar) increased after the priming and peaked at day 7 post-
vaccination but the increases were not significant. G2Na/AL
rapidly and significantly boosted the RSV-A Ab reactivity (black
bar), which then slowly declined. On D148, Ab titres were not
significantly different from those of mice receiving empty PLGA.
In contrast, G2Na/PLGA induced a biphasic increase in RSV-A
titres: a first peak observed on D56, and a second one on D148
(striped bar). At this time point, RSV-A titres were significantly
higher compared to both G2Na/AL- and empty PLGA-immu-
nised mice. Those kinetics probably reflected the intermittent
release of G2Na from PLGA microspheres. Although the kinetics
of in vivo release of Ag protein was unknown, our hypothesis is that:
the first Ab peak response was due to diffusion of PLGA surface-
absorbed G2Na protein and the second Ab peak response was
mainly due to complete hydrolysis of the polymer which released
all the encapsulated G2Na Ag. Minor continuous release of Ag
might happen in between. This type of release was difficult to
standardise as was described with microencapsulated tetanus
toxoid vaccine [31]. Further studies with different formulations
(different type of PLGA size) should be conducted in order to
optimise the appropriated burst release ot the Ag.
We also examined the RSV-A-specific avidity of IgG following a
single injection of either G2Na/AL or G2Na/PLGA in RSV-A
primed mice (Fig. 7C). The avidity was determined by ELISA
elution using ammonium thiocyanate (NH4SCN) as chaotropic
agent, as described [33,49]. Results are expressed as the avidity
index (AI), the concentration of thiocyanate required to elute 50%
of Ab, and as proportions of high-avidity, which was defined for
this antigen as the proportion of Ab molecules that remain bound
to the plates at NH4SCN concentration $3 mol/L ($3 M). For
clarity we represented the % of mice in each immunised group
having low (,3 M; yellow) and high ($3 M; red) avidity,
respectively at days 28 (left panel) and 148 (right panel) post-
immunisation with G2Na. One month after G2Na immunisation,
almost all mice had low avidity RSV-A antibodies. In contrast, by
day 148 post G2Na immunisation, either adsorbed to Alum or
encapsulated in PLGA microspheres, elicited a dramatic increase
in high avidity RSV-A antibodies.
Discussion
In this study, we have comprehensively addressed a number of
important issues relating to the use of a recombinant protein
incorporating the central conserved domain of the RSV G protein
as a subunit RSV vaccine. First, we demonstrated that a carrier
protein fusion partner, in the form of DTa, DTb or BB, did not
enhance the immunogenicity or protective efficacy of G2Na
against homologous virus challenge. This constrasts with our
previous work, in which BBG2Na was found to potentiate anti-
Figure 4. Immunogenicity of G2Na, G2Nb, G2ab and G2Na+G2Nb in mice. Groups of animals were immunised im twice with Ag/Alum
according to experimental protocol outlined in (A). We determined ELISA IgG Ab titre induced respectively by G2Na (dark blue), G2Nb (white), G2ab
(stripe) and G2Na+G2Nb (light blue) on D29, D45 and D60, against (B) G2Na (C) G2Nb and on D60 (D) RSV-A (Long) on the left panel and RSV-B (8/60)
on the right panel.
doi:10.1371/journal.pone.0034331.g004
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routes of antigen administration (subcutaneous versus im or ip)
might account for these discrepancies. In the current study, the
capacity of ip or im G2Na, formulated in Alum, to induce
protective immunity against an RSV-A challenge was unambig-
uously demonstrated in 2 animal models, mice and cotton rats.
As RSV strains are divided into subgroups based primarily on G
protein and gene heterogeneity, it was important to address the
capacity for induction of heterosubtypic protective immunity by
RSV-A- and/or B-derived G fragments. Surprisingly, G2Na was
Figure 5. Immunogenicity and protective efficacy conferred by
G2Na against heterologous challenge in mice. Groups of mice
were immunised ip twice with either 0.5 mgo r3mg of Ag in Alum
according to the experimental protocol outlined in (A). After the 2
nd
injection, we determined (B) by ELISA IgG Ab titre against G2Na (light
blue) left panel, RSV-A (dark blue) middle panel and RSV-B (green) right
panel. Immunised mice were divided into 2 groups (n=5), before
challenge with either RSV-A (10
5 TCID50) and RSV-B (10
6 TCID50).
Protective efficacy was evaluated (C) by determining the titre in the
lungs (expressed as Log10 TCID50/g lungs) of RSV-A (left panel, in dark
blue) and RSV-B (right panel, in green). Dotted line represents the
limited detection of RSV in the lungs.
doi:10.1371/journal.pone.0034331.g005
Figure 6. Persistence of Ab induced by G2Na in cotton rats and
protective efficacy against RSV-A. Groups of animals were
immunised im twice by Ag/Alum according to the experimental
protocol outlined in (A). We studied the duration of Ab induced (B)
by determining IgG Ab titre up to D148 against RSV-A Long strain (blue
circle), RSV-A BT2a clinical strain (red square) and RSV-B CH18537 strain
(green triangle). Protective efficacy of G2Na Ab induced against RSV-A
challenge (10
5TCID50) was evaluated in comparison to SynagisH (C) by
determining titre (expressed as Log10 (TCID50)/g lungs titre of
immunised and treated animals. From left to right: PBS control
immunised group, G2Na immunised group and SynagisH (5 mg/Kg)
treated group.
doi:10.1371/journal.pone.0034331.g006
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mice were immunised im once according to the experimental protocol outlined in (A). We monitored Ab induction on D0, D7, D28, D56, D92 and
D148 by ELISA IgG (B) anti-RSV-A IgG induced by empty PLGA (white bars), by G2Na/AL (blue bars), and by G2Na/PLGA (striped blue bars). Results are
expressed as Arbitrary Units (AU)/ml using a positive control serum as a reference. * p,0.05. We determined affinity maturation of each serum Ab
(see Materials and Methods) and summarised it in (C) bar graphic representation of % of animals with low avidity Ab (,3 M) in yellow and with high
avidity Ab ($3 M) in red on D28 (left panel) and on D148 (right panel). In the panels from left to right: empty PLGA group, G2Na/AL group and G2Na/
PLGA group.
doi:10.1371/journal.pone.0034331.g007
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part at inducing Abs reactive with both RSV-A and B.
Furthermore, genetically fusing or admixing the respective RSV-
A and B G2N antigens did not enhance these responses. The poor
immunogenicity of G2Nb contrasts with the work of Simard et al
[36], who showed that the peptide B174187.S186, corresponding
to amino acid res. 174–187 of RSV-B G, induced protective anti-
RSV-B Ab responses. The B174187.S186 peptide contains the 2
conserved Cys res. (Cys176-Cys182), while the third Cys186 was
substituted by Ser. It is noticed that the corresponding native G
peptide 174–187 contains only 3 Cys, the substitution of the
Cys186 to Ser prevented uncorrected disulfide bonds. Further-
more, Murata et al. [38] recently showed that the central domain
of G from both RSV subtypes (aa151–190) had high reactivity to
sera from adults infected with RSV-A or B and they suggested that
peptides from either the A or B strains might be sufficient to elicit
viral subtype-independent Ab production and protective efficacy.
The poor immunogenicity and protective efficacy of G2Nb might
be explained by inappropriate protein folding, although this
remains to be proven. While the level of Abs induced by G2Na
reacted in a dose-dependent manner with both RSV-A and RSV-
B, the reactivity with RSV-B was clearly inferior. Thus, the
possibility remains that RSV-B reactivity following G2Na
vaccination may be insufficient to protect from RSV-B. G2Na
dose-optimisation experiments will be required to maximise such
responses. The series of proteins or peptides of RSV-B should be
redesigned in order to get the appropriated conformational
‘‘protectopes’’.
The native F protein is another potential candidate to be
considered because its aa sequence is highly conserved between A
and B strains. However, extraction and purification of F protein
from infected eukaryotic cells that are appropriate for human
vaccine use are still problematic for industrial development
[39,40]. Recently, the production of recombinant F protein (with
no transmembrane and no cytoplasmic tail) in a soluble
pretriggered form from 293T mammalian cells was described
[41]. Whether or not this may be scaled up to industrial
production remains to be determined, as does the protective
efficacy and immunogenicity of the final product.
The duration of protective immunity following vaccination is
another critical parameter for any vaccine. Our anti-RSV-A Ab
responses and protection against homologous virus challenge, are
promising on this account. The duration of the experiment (148
days) corresponds with an entire RSV season in temperate zones
[3]. The persistence of strong protective immunity in the cotton rat
model for this period suggests that the G2Na/Alum formulation
might constitute a suitable vaccine for humans. The fact that
elevated Ab reactivity to a recent RSV-A clinical isolate and RSV-
B also persisted for the duration of the experiment is also very
encouraging.
In view of the devastating history of the Alum-adjuvanted
formalin-inactivated RSV vaccine in infants in the 1960s [4], a
subunit RSV vaccine is unlikely to be administered to infants that
are immunologically naive to RSV without a comprehensive
understanding of the mechanisms of the enhanced pathology.
Although extensive animal studies demonstrated that BBG2Na did
not induce FI-RSV-like immunopathology [22,42,43,44,45], the
immunopathogenic potential of G2Na without the BB part
remains to be determined. Increasing epidemiological evidence
indicates that RSV infection causes considerable morbidity and
mortality in the elderly [1,36]. Because they have been repeatedly
infected throughout life with RSV and have developed a pattern of
safe immune responses, they should not be susceptible to the
vaccine-mediated enhanced pathogenesis phenomenon described
in young infants.
Ideally, an RSV vaccine should confer protection against both
RSV-A and RSV-B strains. For this purpose, antigens originating
from both strains might be required. Native Ag purified from RSV
infected cells or recombinant eukaryotic expression (FG expressed
in baculovirus) have been studied in clinical trials [8,46,47,48].
However, native Ag purified from RSV infected mammalian cells
in industrial scale still pose considerable problems with regard to
yield and cost. Therefore, a recombinant vaccine, such as G2Na,
produced in E. coli with high yield and low cost, may be sufficient
and safe in this target population. As already described for lived
vaccines [49], the presence of pre-existing anti-RSV Abs in this
population may compromise such a vaccine. However, the data
presented in Fig. 7 suggest that G2Na, formulated in either Alum
or PLGA, is immunogenic in mice in the presence of pre-existing
anti-RSV-A Abs. The persistence of the Ab responses for at least
148 days was also very encouraging. The significantly elevated
anti-RSV-A Ab responses at the end of the experiment in mice
immunised with G2Na/PLGA remains to be correlated to
increased protective efficacy to demonstrate that this is a
promising formulation. Importantly, we provide robust evidence
that vaccination with different G2Na formulations in the presence
of anti-RSV-Abs did not compromise avidity maturation of the
Abs over time.
In conclusion, our study clearly demonstrated that G2Na has
many characteristics appropriate for a vaccine antigen against
RSV in the elderly. For the seronegative infant target population,
it should be carefully monitored in terms of immunopathology in
animal models. This promising Ag could be associated with an
RSV-B G peptide component or F protein, and/or formulated
with a specific immune response driving adjuvant (e.g., TLR
agonists) to achieve both safety and protective efficacy against
RSV.
Supporting Information
Figure S1 Encapsulation of G2Na in PLGA [poly(D,L-
lactide-co-glycolide]. Schematic representation of the encap-
sulation as described in detail in Materials and Methods. The Ag
microencapsulation efficiency was evaluated to 68%. On the
upper right, we show micro photographs from electronic
microscopy of encapsulated microspheres in order to evaluate
the homogeneity of the recovered PLGA. Graph of distribution of
size showed an average diameter of 14.8 mm.
(TIF)
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